IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Corebridge Financial Inc.

Corebridge Financial Inc. lessened its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 4.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 27,912 shares of the company's stock after selling 1,443 shares during the quarter. Corebridge Financial Inc.'s holdings in IDEXX Laboratories were worth $11,540,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. FSA Wealth Management LLC acquired a new stake in IDEXX Laboratories in the 3rd quarter worth approximately $25,000. Rialto Wealth Management LLC purchased a new stake in shares of IDEXX Laboratories during the fourth quarter valued at $30,000. Retirement Wealth Solutions LLC acquired a new position in shares of IDEXX Laboratories in the 4th quarter valued at $31,000. Kestra Investment Management LLC purchased a new position in IDEXX Laboratories in the 4th quarter worth $38,000. Finally, Crews Bank & Trust acquired a new stake in IDEXX Laboratories during the 4th quarter worth about $41,000. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on IDXX. Morgan Stanley reduced their price objective on IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating for the company in a research note on Wednesday, January 29th. Bank of America lifted their price objective on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a research note on Tuesday, February 4th. Piper Sandler increased their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a research note on Monday, February 10th. Barclays boosted their target price on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a research report on Tuesday, February 4th. Finally, Leerink Partnrs raised IDEXX Laboratories to a "strong-buy" rating in a research report on Monday, December 2nd. Four investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $533.75.

Remove Ads

IDEXX Laboratories Price Performance

Shares of IDEXX Laboratories stock traded down $6.67 on Friday, reaching $415.87. The company's stock had a trading volume of 470,167 shares, compared to its average volume of 581,913. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The company has a market capitalization of $33.71 billion, a P/E ratio of 38.98, a PEG ratio of 3.41 and a beta of 1.39. The stock has a 50-day moving average price of $437.07 and a 200-day moving average price of $443.27. IDEXX Laboratories, Inc. has a 52-week low of $398.50 and a 52-week high of $548.88.

Insider Buying and Selling

In other IDEXX Laboratories news, EVP George Fennell sold 9,986 shares of the business's stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the sale, the executive vice president now directly owns 8,176 shares in the company, valued at approximately $3,781,645.28. The trade was a 54.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director M Anne Szostak sold 3,000 shares of the firm's stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the transaction, the director now owns 3,061 shares in the company, valued at approximately $1,426,242.34. This trade represents a 49.50 % decrease in their position. The disclosure for this sale can be found here. 2.11% of the stock is owned by insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.